This inventor holds 2 USPTO granted patents. Top assignee: Hangzhou Converd Co., Ltd.. Active years: 2021-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Zhejiang, CN (2021)
- Hangzhou, CN (2022)
Company Filing History:
Years Active: 2021-2022
Title: Yanjun Zheng: Innovator in Oncolytic Virus Therapy
Introduction
Yanjun Zheng is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of immunotherapy, particularly through his innovative use of oncolytic viruses in cancer treatment. With a total of 2 patents, Zheng is at the forefront of developing new therapeutic methods that combine oncolytic therapy and immunotherapy.
Latest Patents
Zheng's latest patents include groundbreaking inventions aimed at improving cancer treatment. The first patent focuses on the "Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancers." This invention provides a method for using selectively replicating oncolytic viruses to prepare immunostimulants for treating tumors, without the need for exogenous immunoregulatory genes. The second patent, titled "In vivo individualized systemic immunotherapeutic method and device," outlines a comprehensive method for enhancing the immune response at tumor sites. This method involves increasing the release of tumor antigens, enhancing the presence of proteins that interact with these antigens, and improving the function of immune effector cells, ultimately leading to a significantly improved therapeutic effect.
Career Highlights
Yanjun Zheng is associated with Hangzhou Converd Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to integrating innovative therapies that can provide better outcomes for cancer patients.
Collaborations
Zheng collaborates with notable colleagues in his field, including Ronghua Zhao and Fang Hu, who contribute to his research endeavors. Their combined expertise enhances the potential for breakthroughs in cancer treatment.
Conclusion
Yanjun Zheng's innovative work in the application of oncolytic viruses represents a significant advancement in cancer therapy. His patents reflect a deep understanding of immunotherapy and its potential to improve patient outcomes. Zheng's contributions are paving the way for future developments in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile